Opinion statement
Optimal therapy for pancreatic adenocarcinoma requires surgical removal with tumor-free margins. Superior outcomes have been reported for high-volume centers incorporating a multidisciplinary approach. Postoperative (“adjuvant”) chemotherapy and radiation should be considered in patients with successfully resected primary tumors. Combined modality treatment with chemotherapy and radiation should be considered for locally advanced, unresectable tumors. Gemcitabine can provide symptom relief and a modest improvement in survival for patients with metastatic disease. Strict attention to relief of symptoms such as pain, depression, anorexia/ cachexia, and jaundice is essential in all patients with pancreatic cancer. All patients with pancreatic cancer should be encouraged to enter clinical trials of new therapies, given that long-term survival for all stages remains poor.
Similar content being viewed by others
References and Recommended Reading
Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7–33.
Lowenfels AB, Maisonneuve P: Pancreatico-biliary malignancy: prevalence and risk factors. Ann Oncol 1999, 10(suppl 4):S1-S3.
Caldas C, Hahn SA, da Costa LT, et al.: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994, 8:27–32.
Whelan AJ, Bartsch D, Goodfellow PJ: Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumorsuppressor gene. N Engl J Med 1995, 333:975–977.
Schutte M, Hruban RH, Hedrick L, et al.: DPC4 gene in various tumor types. Cancer Res 1996, 56:2527–2530.
Rozenblum E, Schutte M, Goggins M, et al.: Tumor- suppressive pathways in pancreatic carcinoma. Cancer Res 1997, 57:1731–1734.
Goggins M, Schutte M, Lu J, et al.: Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996, 56:5360–5364.
Hruban RH, Goggins M, Parsons J, Kern SE: Progression model for pancreatic cancer. Clin Cancer Res 2000, 6:2969–2972. An interesting review paper that develops a genetic progression model for pancreatic cancer.
Gouma DJ, Nieveen van Dijkum EJM, Obertop H: The standard diagnostic work-up and surgical treatment of pancreatic head tumours. Eur J Surg Oncol 1999, 25:113–123.
Zeman RK, Cooper C, Zeiberg AS, et al.: TNM staging of pancreatic carcinoma using helical CT. Am J Roentgenol 1997, 169:459–464.
Faigel DO, Ginsberg GG, Bentz JS, et al.: Endoscopic ultrasound-guided real-time fine-needle aspiration biopsy of the pancreas in cancer patients with pancreatic lesions. J Clin Oncol 1997, 15:1439–1443.
Gress FG, Hawes RH, Savides TJ, et al.: Role of EUS in the preoperative staging of pancreatic cancer: a large single-center experience. Gastrointest Endosc 1999, 50:786–791.
Ritts RE, Nagorney DM, Jacobsen DJ, et al.: Comparison of preoperative serum CA 19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas 1994, 9:707–716.
Fleming ID, Cooper JS, Henson DE, et al.: AJCC Cancer Staging Manual, edn 5. Philadelphia: Lippincott-Raven Publishers; 1997:121–124.
Povoski SP, Karpeh MS, Conlon KC, et al.: Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy. Ann Surg 1999, 230:131–142.
Pisters PWT, Hudec WA, Lee JE, et al.: Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol 2000, 18:860–867.
Mueller PR, van Sonnenberg E, Ferrucci JT, et al.: Percutaneous biliary drainage: technical and catheter-related problems in 200 procedures. AJR Am J Roentgenol 1982, 138:17–23.
Sohn TA, Lillemoe KD, Cameron JL, et al.: Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg 1999, 188:658–666.
Conlon KC, Dougherty E, Klimstra DS, et al.: The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg 1996, 223:134–140.
Merchant NB, Conlon KC, Saigo P, et al.: Positive peritoneal cytology predicts unresectability of pancreatic adenocarcinoma. J Am Coll Surg 1999, 188:421–426.
Cameron JL: The current management of carcinoma of the head of the pancreas. Annu Rev Med 1995, 46:361–370.
Conlon KC, Klimstra DS, Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5- year survivors. Ann Surg 1996, 223:273–279.
Begg CB, Cramer LD, Hoskins WJ, Brennan MF: Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998, 280:1747–1751.
Yeo CJ, Cameron JL, Lillemoe KD, et al.: Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995, 221:721–731.
Harrison LE, Klimstra DS, Brennan MF: Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg 1996, 224:342–347.
Bold RJ, Charnsangavej C, Cleary KR, et al.: Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg 1999, 3:233–243.
Yeo CJ, Cameron JL, Sohn TA, et al.: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s. Pathology, complications, and outcomes. Ann Surg 1997, 226:248–257. This extensive series from a leading high-volume surgery center summarizes the authors' experience in performing 650 pancreaticoduodenectomies for a variety of disorders. Pathology, surgical procedures, and operative morbidity and mortality are described, including a very low 1.4% operative mortality rate.
Cameron JL, Crist DW, Sitzmann JV, et al.: Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991, 161:120–124.
van den Borsh RP, van der Schelling GP, Klinkenbijl JHG, et al.: Guidelines for the application of surgery and endoprostheses in the palliation of obstructive jaundice in advanced cancer of the pancreas. Ann Surg 1994, 219:18–24.
Deziel DJ, Wilhelmi B, Staren ED, Doolas A: Surgical palliation for ductal adenocarcinoma of the pancreas. Am Surg 1996, 62:582–588.
de Rooij PD, Rogatko A, Brennan MF: Evaluation of palliative surgical procedures in unresectable pancreatic cancer. Br J Surg 1991, 78:1053–1058.
Griffin JF, Smalley SR, Jewell W, et al.: Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990, 66:56–61.
Kalser MH, Ellenberg SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899–903.
Klinkenbijl JH, Jeekel J, Sahmoud T: Adjuvant radiotherapy and 5-Fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230:776–784.
Whittington R, Neuberg D, Tester WJ, et al.: Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a Phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol 1995, 13:227–232.
Burris HA, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403–2413. This important study established the current standard treatment for metastatic pancreatic cancer. Gemcitabine, when compared with 5-FU bolus therapy, demonstrated a modest improvement in survival as well as clinical benefit response.
Hoffman JP, Lipsitz S, Pisansky T, et al.: Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998, 16:317–323.
Moertel CG, Frytak S, Hahn RG, et al.: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-Fluorouracil), and high dose radiation + 5-Fluorouracil. The gastrointestinal tumor study group. Cancer 1981, 48:1705–1710.
Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988, 80:751–755.
Cullinan S, Moertel CG, Wieand HS, et al.: A phase III trial on the therapy of advanced pancreatic carcinoma. Cancer 1990, 65:2207–2212.
Caraceni A, Portenoy RK: Pain management in patients with pancreatic carcinoma. Cancer 1996, 78:639–653.
Cancer pain relief and palliative care: report of a WHO expert committee. WHO Tech Rep Ser 1990,804:9.
Kelsen DP, Portenoy RK, Thaler HT, et al.: Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995, 13:748–755.
Wigmore SJ, Plester CE, Richardson RA, Fearon KCH: Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 1997, 75:106–109.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cohen, S.J., Pinover, W.H., Watson, J.C. et al. Pancreatic cancer. Curr. Treat. Options in Oncol. 1, 375–386 (2000). https://doi.org/10.1007/s11864-000-0065-2
Issue Date:
DOI: https://doi.org/10.1007/s11864-000-0065-2